Literature DB >> 11230750

Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization.

S Zucchelli1, R Roccasecca, A Meola, B B Ercole, R Tafi, J Dubuisson, G Galfré, R Cortese, A Nicosia.   

Abstract

The hypervariable region 1 (HVR1) of the putative envelope protein E2 of hepatitis C virus (HCV) contains a principal neutralization epitope, and anti-HVR1 antibodies have been shown to possess protective activity in ex vivo neutralization experiments. However, the high rate of variability of this antigenic fragment may play a major role in the mechanism of escape from host immune response and might represent a major obstacle to developing an HCV vaccine. Thus, even if direct experimental evidence of the neutralizing potential of anti-HVR1 antibodies by active immunization is still missing, the generation of a vaccine candidate with a cross-reactive potential would be highly desirable. To overcome the problem of HVR1 variability, we have engineered cross-reactive HVR1 peptide mimics (mimotopes) at the N terminus of the E2 ectodomain in plasmid vectors suitable for genetic immunization. High levels of secreted and biologically active mimotope/E2 chimeras were obtained by transient transfection of these plasmids in cultured cells. All plasmids elicited anti-HVR1 antibodies in mice and rabbits with some of them leading to a cross-reacting response against many HVR1 variants from natural isolates. Epitope mapping revealed a pattern of reactivity similar to that induced by HCV infection. In contrast, plasmids encoding naturally occurring HVR1 sequences displayed either on full-length E2 in the context of the whole HCV structural region, or on a soluble, secreted E2 ectodomain, did not induce a cross-reacting anti-HVR1 response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11230750     DOI: 10.1053/jhep.2001.22175

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

1.  Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes.

Authors:  Heidi Barth; Raffaele Cerino; Mirko Arcuri; Marco Hoffmann; Peter Schürmann; Mohammed I Adah; Bettina Gissler; Xiping Zhao; Valeria Ghisetti; Bruna Lavezzo; Hubert E Blum; Fritz von Weizsäcker; Alessandra Vitelli; Elisa Scarselli; Thomas F Baumert
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

2.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2.

Authors:  RosaMaria Roccasecca; Helenia Ansuini; Alessandra Vitelli; Annalisa Meola; Elisa Scarselli; Stefano Acali; Monica Pezzanera; Bruno Bruni Ercole; Jane McKeating; Asutosh Yagnik; Armin Lahm; Anna Tramontano; Riccardo Cortese; Alfredo Nicosia
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

4.  Cross-reactivity of hypervariable region 1 chimera of hepatitis C virus.

Authors:  Bing-Shui Xiu; Shi-Gan Ling; Xiao-Guo Song; He-Qiu Zhang; Kun Chen; Cui-Xia Zhu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

Review 5.  Neutralizing antibody response to hepatitis C virus.

Authors:  Yong Wang; Zhen-Yong Keck; Steven K H Foung
Journal:  Viruses       Date:  2011-11-02       Impact factor: 5.048

Review 6.  The past, present and future of neutralizing antibodies for hepatitis C virus.

Authors:  Jonathan K Ball; Alexander W Tarr; Jane A McKeating
Journal:  Antiviral Res       Date:  2014-02-26       Impact factor: 5.970

7.  Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.

Authors:  Milena Lange; Melanie Fiedler; Dorothea Bankwitz; William Osburn; Sergei Viazov; Olena Brovko; Abdel-Rahman Zekri; Yury Khudyakov; Michael Nassal; Paul Pumpens; Thomas Pietschmann; Jörg Timm; Michael Roggendorf; Andreas Walker
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.